Alnylam Pharmaceuticals (ALNY) Leases (2017 - 2025)
Historic Leases for Alnylam Pharmaceuticals (ALNY) over the last 14 years, with Q4 2025 value amounting to $194.9 million.
- Alnylam Pharmaceuticals' Leases rose 197.12% to $194.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $194.9 million, marking a year-over-year increase of 197.12%. This contributed to the annual value of $194.9 million for FY2025, which is 197.12% up from last year.
- As of Q4 2025, Alnylam Pharmaceuticals' Leases stood at $194.9 million, which was up 197.12% from $191.4 million recorded in Q3 2025.
- In the past 5 years, Alnylam Pharmaceuticals' Leases registered a high of $238.1 million during Q2 2021, and its lowest value of $191.1 million during Q4 2024.
- Its 5-year average for Leases is $210.7 million, with a median of $206.1 million in 2023.
- In the last 5 years, Alnylam Pharmaceuticals' Leases skyrocketed by 720.04% in 2021 and then plummeted by 910.54% in 2024.
- Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Leases stood at $231.7 million in 2021, then fell by 7.14% to $215.1 million in 2022, then decreased by 7.16% to $199.7 million in 2023, then decreased by 4.3% to $191.1 million in 2024, then grew by 1.97% to $194.9 million in 2025.
- Its Leases stands at $194.9 million for Q4 2025, versus $191.4 million for Q3 2025 and $192.4 million for Q2 2025.